Search

Joan D Mannick

from Weston, MA
Age ~65
Get Report
Also known as:
Joan B Mannick, Joan Dr Mannick, Joan B Talcott, Jb Mannick
Phone and address:
27 Carroll Cir, Cherry Brook, MA 02493
(781) 642-9906
Connected to:
Molly J Mannick, 38Richard O Mannick, 70Amy B Mannie, 54Eboni G Mannie, 41Tangela D Mannie, 48Travel T Mannie, 35Yolanda R Mannie, 45Daniel Manniello, 65Sherry L Manniello, 73Whitney L Mannies, 41

Joan Mannick Phones & Addresses

  • 27 Carroll Cir, Weston, MA 02493 (781) 642-9906
  • Boston, MA
  • Wellesley, MA
  • Rancho Mirage, CA
  • Riverside, CA

Work

Company: UNIVERSITY OF MASS MED SCHOOL Address: 364 Plantation St Suite 222, Worcester, MA 01605 Phones: (508) 856-7511

Education

School / High School: Harvard Medical School 1985

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Infectious Disease, 1990

Specialities

Infectious Disease Medicine

Professional Records

Medicine Doctors

Joan Mannick Photo 1

Dr. Joan B Mannick, Cambridge MA - MD (Doctor of Medicine)

View page
Specialties:
Infectious Disease Medicine
Address:
220 Massachusetts Ave, Cambridge, MA 02139
(617) 871-5659 (Phone)

UNIVERSITY OF MASS MED SCHOOL
364 Plantation St Suite 222, Worcester, MA 01605
(508) 856-7511 (Phone)

55 Lake Ave N, Worcester, MA 01655
(508) 856-7511 (Phone)
Certifications:
Infectious Disease, 1990
Internal Medicine, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
220 Massachusetts Ave, Cambridge, MA 02139

55 Lake Ave N, Worcester, MA 01655

UNIVERSITY OF MASS MED SCHOOL
364 Plantation St Suite 222, Worcester, MA 01605

Brigham and Women's Hospital
75 Francis Street, Boston, MA 02115

Dana - Farber Cancer Institute
450 Brookline Avenue, Boston, MA 02115

UMass Memorial Medical Center - University Campus
55 Lake Avenue North, Worcester, MA 01655
Education:
Medical School
Harvard Medical School
Graduated: 1985
Medical School
Brigham and Womens Hospital
Graduated: 1985
Medical School
Harvard Joint Prgrm
Graduated: 1985
Joan Mannick Photo 2

Joan B Mannick, Cambridge MA

View page
Specialties:
Infectious Disease Specialist
Address:
220 Massachusetts Ave, Cambridge, MA 02139
55 Lake Ave N, Worcester, MA 01655
Education:
Harvard Medical School - Doctor of Medicine
Massachusetts General Hospital - Fellowship - Infectious Disease (Internal Medicine)
Brigham & Women's Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)

Resumes

Resumes

Joan Mannick Photo 3

Chief Medical Officer

View page
Location:
27 Carroll Cir, Weston, MA 02493
Industry:
Pharmaceuticals
Work:
Restorbio
Chief Medical Officer
Novartis Institutes For Biomedical Research (Nibr) 2010 - 2014
Director, Translational Medicine
Novartis Institutes For Biomedical Research (Nibr) 2010 - 2014
Executive Director, Translational Medicine
Sanofi Genzyme 2007 - 2010
Medical Director
Education:
Harvard Medical School
Doctor of Medicine, Doctorates Harvard University
Bachelors, Bachelor of Arts, History
Skills:
Clinical Development
Clinical Trials
Pharmaceutical Industry
Drug Development
Biotechnology
Translational Medicine
Clinical Research
Life Sciences
Lifesciences
Medicine
Immunology
Infectious Diseases
Gcp
Drug Discovery
Diabetes
Pharmacovigilance
Regulatory Submissions
Neurology
Cro
Joan Mannick Photo 4

Joan Mannick

View page

Publications

Us Patents

System For Detection Of Nitrosylated Proteins

View page
US Patent:
20040203068, Oct 14, 2004
Filed:
Dec 12, 2002
Appl. No.:
10/319457
Inventors:
Joan Mannick - Weston MA, US
Benjamin Gaston - Charlottesville VA, US
Barbara Leinweber - Coravallis OR, US
International Classification:
G01N033/53
US Classification:
435/007100
Abstract:
The present invention describes a novel, simplified method for detecting and monitoring whether the presence of nitrosylated proteins, such as S-nitrosoproteins, in a biological sample using fluorescence detection. The present invention further describes a method which can both quantify and identify the nature of nitrosylated proteins, which method is useful for monitoring both normal and disease states, in the development and screening of potential therapeutic drug species.

System For Detection Of S-Nitrosoproteins

View page
US Patent:
20080199967, Aug 21, 2008
Filed:
Jan 17, 2008
Appl. No.:
12/016094
Inventors:
Joan Mannick - Weston MA, US
Benjamin Gaston - Charlottesville VA, US
Barbara Leinweber - Tucson AZ, US
Assignee:
UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER - Boston MA
UNIVERSITY OF VIRGINIA PATENT FOUNDATION - Charlottesville VA
International Classification:
G01N 33/68
US Classification:
436 86
Abstract:
The present invention describes a novel, simplified method for detecting and monitoring the presence of nitrosylated proteins, such as S-nitrosoproteins, in a biological sample using fluorescence detection. The present invention further describes a method which can both quantify and identify the nature of nitrosylated proteins, which method is useful for monitoring both normal and disease states, in the development and screening of potential therapeutic drug species.

Phosphoglycerate Kinase 1 (Pgk) Promoters And Methods Of Use For Expressing Chimeric Antigen Receptor

View page
US Patent:
20230052970, Feb 16, 2023
Filed:
Oct 3, 2022
Appl. No.:
17/937488
Inventors:
- Basel, CH
- Philadelphia PA, US
David Glass - Cambridge MA, US
Thomas Huber - Basel, CH
Julia Jascur - Basel, CH
Carl H. June - Merion Station PA, US
Jihyun Lee - Wynnewood PA, US
Joan Mannick - Cambridge MA, US
Michael C. Milone - Cherry Hill NJ, US
Leon Murphy - Cambridge MA, US
Avery D. Posey - Philadelphia PA, US
Huijuan Song - Shanghai, CN
Yongqiang Wang - Shanghai, CN
Lai Wei - Shanghai, CN
Qilong Wu - Brighton MA, US
Qiumei Yang - Shanghai, CN
Jiquan Zhang - Shanghai, CN
International Classification:
C07K 16/28
A61K 35/17
C07K 16/30
C07K 14/705
A61P 35/02
A61P 35/00
A61K 48/00
C07K 14/725
C12N 15/86
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Regulatable Chimeric Antigen Receptor

View page
US Patent:
20230026049, Jan 26, 2023
Filed:
Apr 28, 2022
Appl. No.:
17/661207
Inventors:
- Basel, CH
- Philadelphia PA, US
David Jonathan Glass - Cambridge MA, US
Brian Granda - Salisbury MA, US
John Hastewell - Cambridge MA, US
Andreas Loew - Boston MA, US
Joan Mannick - Cambridge MA, US
Michael C. Milone - Moorestown NJ, US
Leon Murphy - Cambridge MA, US
William Raj Sellers - Cambridge MA, US
Huijuan Song - Shanghai, CN
Brian Edward Vash - Cambridge MA, US
Jan Weiler - Cambridge MA, US
Qilong Wu - Shanghai, CN
Li Zhou - Cambridge MA, US
International Classification:
C07K 16/28
C07K 14/725
C07K 14/705
C07K 14/74
C12N 9/90
C12N 9/12
C07K 14/71
A61K 31/436
A61K 35/17
Abstract:
Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Pharmaceutical Combination Of Everolimus With Dactolisib

View page
US Patent:
20210030741, Feb 4, 2021
Filed:
Nov 21, 2019
Appl. No.:
16/690211
Inventors:
- Basel, CH
Joan Mannick - Cambridge MA, US
Leon Murphy - Cambridge MA, US
International Classification:
A61K 31/4745
A61K 31/436
Abstract:
The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.

Treatment Of Cancer Using A Cd123 Chimeric Antigen Receptor

View page
US Patent:
20210002377, Jan 7, 2021
Filed:
May 27, 2020
Appl. No.:
16/884867
Inventors:
- Basel, CH
- Philadelphia PA, US
David Jonathan Glass - Cambridge MA, US
Saad Kenderian - Philadelphia PA, US
Andreas Loew - Boston MA, US
Joan Mannick - Cambridge MA, US
Michael C. Milone - Cherry Hill NJ, US
Leon Murphy - Cambridge MA, US
David L. Porter - Springfield PA, US
Marco Ruella - Ardmore PA, US
Yongqiang Wang - Shanghai, CN
Qilong Wu - Shanghai, CN
Jiquan Zhang - Shanghai, CN
International Classification:
C07K 16/28
A61K 39/00
C07K 16/24
C12N 5/0783
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Methods For B Cell Preconditioning In Car Therapy

View page
US Patent:
20200339651, Oct 29, 2020
Filed:
Dec 9, 2019
Appl. No.:
16/708397
Inventors:
- Basel, CH
- Philadelphia PA, US
David Jonathan Glass - Cambridge MA, US
Carl H. June - Merion Station PA, US
Joan Mannick - Cambridge MA, US
Michael C. Milone - Cherry Hill NJ, US
Leon Murphy - Cambridge MA, US
Gabriela Plesa - Blue Bell PA, US
Huijuan Song - Shanghai, CN
Qilong Wu - Brighton MA, US
International Classification:
C07K 14/725
C07K 14/705
C07K 16/28
C07K 16/30
A61P 35/00
A61K 31/436
A61K 31/675
A61K 35/17
A61K 38/17
A61K 39/395
A61K 45/06
A61N 5/10
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.

Treatment Of Cancer Using Anti-Cd19 Chimeric Antigen Receptor

View page
US Patent:
20190388471, Dec 26, 2019
Filed:
Jun 7, 2019
Appl. No.:
16/435257
Inventors:
- Basel, CH
- Philadelphia PA, US
Marcela Maus - Lexington MA, US
Mariusz Wasik - Ardmore PA, US
Saar Gill - Philadelphia PA, US
Joseph A. Fraietta - Williamstown NJ, US
Marco Ruella - Ardmore PA, US
John Byrd - Columbus OH, US
Jason Dubovsky - Columbus OH, US
Amy Johnson - Dublin OH, US
Natarajan Muthusamy - Galloway OH, US
Saad Kenderian - Philadelphia PA, US
Joan Mannick - Cambridge MA, US
David Jonathan Glass - Cambridge MA, US
Leon Murphy - Cambridge MA, US
Jennifer Brogdon - Sudbury MA, US
William Raj Sellers - Cambridge MA, US
Assignee:
Novartis AG - Basel
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 35/17
A61K 39/395
A61K 31/519
A61K 45/06
C07K 14/725
A61K 31/436
A61K 31/53
C12N 5/0783
C07K 16/28
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
Control profile
Joan D Mannick from Weston, MA, age ~65 Get Report